Key result
Edoxaban initiation involves ~72% anticoagulation-naive patients in routine NVAF practice.
Why the study?
The global ETNA-AF programme was initiated to evaluate the effectiveness and safety of edoxaban in patients with non-valvular atrial fibrillation under real-life conditions.
Observational (n=17,769)
Yes
In a global real-world registry of patients with atrial fibrillation prescribed edoxaban, nearly three-quarters were anticoagulation-naive, with notable regional variations in prior antithrombotic use.
Answers are grounded in this paper and cite their sources.
Edoxaban initiation in AF occurs mostly in anticoagulation-naive patients; leaves open whether prior OAC status modifies real-world safety or effectiveness.
Background: Edoxaban has been approved for stroke prevention in patients with atrial fibrillation based on its effectiveness and superior safety compared to warfarin in the controlled ENGAGE AF-TIMI 48 trial. The global ETNA-AF programme was initiated to evaluate the effectiveness and safety of edoxaban in patients under real-life conditions. Purpose and methods: The global ETNA-AF programme combines information from 3 separate registries conducted in Europe, East Asia, and Japan, and will describe the use of edoxaban in routine clinical care, including the safety and efficacy of edoxaban. Data were harmonised, transformed, and integrated into a single database. A total of about 27,000 ETNA-AF patients will be included in the ETNA-AF registries and followed for ≥2 years. We report a snapshot analysis of 17,769 patients focusing on antithrombotic therapy before initiation of edoxaban. At the ESC Congress, data from all available patients will be presented. Results: Of the patients participating in global ETNA-AF, 12855/17769 (72.3%) patients were anticoagulation-naive, 4914/17769 (27.7%) were on oral anticoagulation therapy before edoxaban was initiated, 2806/17769 (15.8%) were on a vitamin K antagonist (VKA), and 2108/17769 (11.8%) were on other non-VKA oral anticoagulants (NOACs). Patients from Korea/Taiwan have the highest percentages of previous use for both a VKA (370/2046 [18.1%]) and other NOACs (500/2046 [24.4%]) followed by Japan (VKA:1019/7227 [14.1%], NOAC:860/7227 [11.9%]), and Europe (VKA:1417/8496 [16.7%], NOAC:748/8496 [8.8%]). Antiplatelet use, mainly aspirin (A) and clopidogrel (C), was highest in Korea/Taiwan (A:281/2046 [13.7%], C:82/2046 [4.0%]) followed by Europe (A:1132/8496 [13.3%], C:189/8496 [2.2%]), and Japan (A:202/7227 [2.8%], C:35/7227 [0.5%]). Table 1 shows antithrombotic therapy before study entry relative to the edoxaban dose at baseline of ETNA-AF.
No takes yet. Share an insight, caveat, or question.
Caterina et al. (2018) conducted an observational in non-valvular atrial fibrillation (n=17,769). Edoxaban was evaluated on Antithrombotic therapy before initiation of edoxaban. Among 17,769 patients with non-valvular atrial fibrillation prescribed edoxaban in routine practice, 72.3% were anticoagulation-naive and 27.7% had prior oral anticoagulation therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: